XML 40 R28.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Reporting (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information, by Segment |
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
| (in thousands)
Revenue | $ | 529 |  |  | $ | 1,339 |  |  | $ | 13,032 |  |  | $ | 4,597 |
Less: |  |  |  |  |  |  |
Research and development employee expense, lab supplies and overhead | 3,194 |  |  | 6,166 |  |  | 9,927 |  |  | 20,174 |
Imdusiran IM-PROVE I, II & III clinical trials expense | 1,073 |  |  | 5,031 |  |  | 4,862 |  |  | 14,430 |
AB-101-001 Phase 1a/1b clinical trial expense | 1,134 |  |  | 2,931 |  |  | 4,771 |  |  | 8,927 |
Other research and development programs expense | 377 |  |  | 145 |  |  | 675 |  |  | 1,696 |
General and administrative expense | 3,044 |  |  | 4,537 |  |  | 12,204 |  |  | 17,396 |
Restructuring expense | 98 |  |  | 3,625 |  |  | 12,636 |  |  | 3,625 |
Other segment expense (1) | 303 |  |  | 367 |  |  | 893 |  |  | 857 |
Add: |  |  |  |  |  |  |
Interest income | 952 |  |  | 1,746 |  |  | 3,191 |  |  | 5,120 |
Segment net loss | $ | (7,742) |  |  | $ | (19,717) |  |  | $ | (29,745) |  |  | $ | (57,388) |
Adjustments and reconciling items | — |  |  | — |  |  | — |  |  | — |
Consolidated net loss | $ | (7,742) |  |  | $ | (19,717) |  |  | $ | (29,745) |  |  | $ | (57,388) |
(1) Other segment expense includes the change in the fair value of contingent consideration, non-cash interest expenses and foreign currency exchange gains and losses.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration